Lipid profile and the variables associated with control of selected lipid parameters in patients of a large multi-specialist hospital in Poland - the Jurasz Lipid Study (JLS).
Marcin Ziółkowski, Jakub Ratajczak, Karolina Obońska, Piotr Adamski, Maciej Banach, Krzysztof Chlebus, Maciej Grymuza, Klaudyna Grzelakowska, Piotr Jankowski, Jacek Konarski, Ewa Laskowska, Piotr Niezgoda, Małgorzata Ostrowska, Elżbieta Ozorowska, Przemysław Podhajski, Jacek Przybylski, Grzegorz Skonieczny, Bożena Sosnowska, Łukasz Szarpak, Małgorzata Topolska, Julia Umińska, Magdalena Krintus, Jacek Kryś, Jacek Kubica
{"title":"Lipid profile and the variables associated with control of selected lipid parameters in patients of a large multi-specialist hospital in Poland - the Jurasz Lipid Study (JLS).","authors":"Marcin Ziółkowski, Jakub Ratajczak, Karolina Obońska, Piotr Adamski, Maciej Banach, Krzysztof Chlebus, Maciej Grymuza, Klaudyna Grzelakowska, Piotr Jankowski, Jacek Konarski, Ewa Laskowska, Piotr Niezgoda, Małgorzata Ostrowska, Elżbieta Ozorowska, Przemysław Podhajski, Jacek Przybylski, Grzegorz Skonieczny, Bożena Sosnowska, Łukasz Szarpak, Małgorzata Topolska, Julia Umińska, Magdalena Krintus, Jacek Kryś, Jacek Kubica","doi":"10.1186/s12944-025-02712-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hyperlipidemia is the most prevalent cardiovascular (CV) risk factors. We aimed to analyze the distribution of lipid parameters and clinical variables associated with elevated and non-elevated selected lipid factors in a cohort of all consecutive patients whose lipid profile was assessed at a multi-specialist clinical center.</p><p><strong>Materials and methods: </strong>This cross-sectional study analyzed electronic medical records of consecutive patients treated between March and November 2024. Lipid parameters measured included: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoprotein B (apoB), and lipoprotein (a) [Lp(a)]. Non-high-density lipoprotein cholesterol (non-HDL-C) was calculated as TC-HDL-C. We used multivariate analysis to identify factors associated with LDL-C, TG, and Lp(a) concentrations.</p><p><strong>Results: </strong>A total of 10,597 patients were included in the analysis. The median lipid concentrations (mg/dL) were: TC 162 (IQR 132-198), LDL-C 94 (IQR 69-129), non-HDL-C 112 (IQR 88-146), apoB 78 (IQR 63-99), and Lp(a) 11 (IQR 5-29). Elevated LDL-C > 100 mg/dL was observed in 45.7% of patients, non-HDL-C > 130 mg/dL in 35.1%, and apoB > 100 mg/dL in 23.2%. A discordance between LDL-C and apoB concentrations was present in 23.7% of patients (p < 0.001), while LDL-C/non-HDL-C and apoB/non-HDL-C discordance rates were 13% and 12.6%, respectively (p < 0.001). Patients at very high CV risk had lower TC, LDL-C, non-HDL-C, and apoB concentrations compared to those with low-to-moderate and high CV risk (p < 0.001) and showed the highest median Lp(a) concentration of 13 mg/dL (IQR 5-31; p = 0.01). Goal achievements of LDL-C < 100 mg/dL, TG < 150 mg/dL, and Lp(a) < 30 mg/dL were associated with lipid-lowering treatment [OR 1.32 (95% CI 1.12-1.52)], atrial fibrillation [OR 1.31 (95% CI 1.11-1.54)], chronic coronary syndromes [OR 1.27 (95% CI 1.05-1.52)], smoking [OR 0.78 (95% CI 0.65-0.95)], BMI [OR 0.98 (95% CI 0.96-0.99)], and age [OR 1.006 (95% CI 1.002-1.009)].</p><p><strong>Conclusion: </strong>The highest proportion of patients with results within the normal range was observed for apoB and the lowest for LDL-C. The highest discordance was observed between apoB/LDL-C, with similar discordance rates between LDL-C/non-HDL-C and apoB/non-HDL-C. Lipid profile control was associated with BMI, atrial fibrillation, age, chronic coronary syndrome, aortic stenosis, diabetes, male gender, lipid-lowering therapy, and smoking. These findings highlight the complexity of lipid management.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"300"},"PeriodicalIF":3.9000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482036/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lipids in Health and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12944-025-02712-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hyperlipidemia is the most prevalent cardiovascular (CV) risk factors. We aimed to analyze the distribution of lipid parameters and clinical variables associated with elevated and non-elevated selected lipid factors in a cohort of all consecutive patients whose lipid profile was assessed at a multi-specialist clinical center.
Materials and methods: This cross-sectional study analyzed electronic medical records of consecutive patients treated between March and November 2024. Lipid parameters measured included: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoprotein B (apoB), and lipoprotein (a) [Lp(a)]. Non-high-density lipoprotein cholesterol (non-HDL-C) was calculated as TC-HDL-C. We used multivariate analysis to identify factors associated with LDL-C, TG, and Lp(a) concentrations.
Results: A total of 10,597 patients were included in the analysis. The median lipid concentrations (mg/dL) were: TC 162 (IQR 132-198), LDL-C 94 (IQR 69-129), non-HDL-C 112 (IQR 88-146), apoB 78 (IQR 63-99), and Lp(a) 11 (IQR 5-29). Elevated LDL-C > 100 mg/dL was observed in 45.7% of patients, non-HDL-C > 130 mg/dL in 35.1%, and apoB > 100 mg/dL in 23.2%. A discordance between LDL-C and apoB concentrations was present in 23.7% of patients (p < 0.001), while LDL-C/non-HDL-C and apoB/non-HDL-C discordance rates were 13% and 12.6%, respectively (p < 0.001). Patients at very high CV risk had lower TC, LDL-C, non-HDL-C, and apoB concentrations compared to those with low-to-moderate and high CV risk (p < 0.001) and showed the highest median Lp(a) concentration of 13 mg/dL (IQR 5-31; p = 0.01). Goal achievements of LDL-C < 100 mg/dL, TG < 150 mg/dL, and Lp(a) < 30 mg/dL were associated with lipid-lowering treatment [OR 1.32 (95% CI 1.12-1.52)], atrial fibrillation [OR 1.31 (95% CI 1.11-1.54)], chronic coronary syndromes [OR 1.27 (95% CI 1.05-1.52)], smoking [OR 0.78 (95% CI 0.65-0.95)], BMI [OR 0.98 (95% CI 0.96-0.99)], and age [OR 1.006 (95% CI 1.002-1.009)].
Conclusion: The highest proportion of patients with results within the normal range was observed for apoB and the lowest for LDL-C. The highest discordance was observed between apoB/LDL-C, with similar discordance rates between LDL-C/non-HDL-C and apoB/non-HDL-C. Lipid profile control was associated with BMI, atrial fibrillation, age, chronic coronary syndrome, aortic stenosis, diabetes, male gender, lipid-lowering therapy, and smoking. These findings highlight the complexity of lipid management.
期刊介绍:
Lipids in Health and Disease is an open access, peer-reviewed, journal that publishes articles on all aspects of lipids: their biochemistry, pharmacology, toxicology, role in health and disease, and the synthesis of new lipid compounds.
Lipids in Health and Disease is aimed at all scientists, health professionals and physicians interested in the area of lipids. Lipids are defined here in their broadest sense, to include: cholesterol, essential fatty acids, saturated fatty acids, phospholipids, inositol lipids, second messenger lipids, enzymes and synthetic machinery that is involved in the metabolism of various lipids in the cells and tissues, and also various aspects of lipid transport, etc. In addition, the journal also publishes research that investigates and defines the role of lipids in various physiological processes, pathology and disease. In particular, the journal aims to bridge the gap between the bench and the clinic by publishing articles that are particularly relevant to human diseases and the role of lipids in the management of various diseases.